The Business of RNAi Therapeutics in 2012

Dirk Haussecker

Open source

DOI
10.1038/mtna.2011.9
Published
2012
Container
Molecular Therapy - Nucleic Acids
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/mtna.2011.9,
  title = {The Business of RNAi Therapeutics in 2012},
  author = {Dirk Haussecker},
  year = {2012},
  journal = {Molecular Therapy - Nucleic Acids},
  doi = {10.1038/mtna.2011.9},
  url = {https://doi.org/10.1038/mtna.2011.9}
}

RIS

TY  - JOUR
TI  - The Business of RNAi Therapeutics in 2012
AU  - Dirk Haussecker
PY  - 2012
JO  - Molecular Therapy - Nucleic Acids
DO  - 10.1038/mtna.2011.9
UR  - https://doi.org/10.1038/mtna.2011.9
ER  - 

APA

Haussecker, D. (2012). The Business of RNAi Therapeutics in 2012. Molecular Therapy - Nucleic Acids. https://doi.org/10.1038/mtna.2011.9

Source records